Syncom Formulations (India) Share Price

Syncom Formulations (India) Ltd

Syncom Formulations (India) Limited, established in 1988 as a private limited company, is a renowned name in the Indian pharmaceutical industry. The company has established itself as a major player in the sector due to its unwavering commitment to quality and consistency. With a robust presence in both the manufacturing and marketing of pharmaceutical products, Syncom has built a reputation for excellence. The company was converted into a public limited company in June 1992, marking a new phase in its journey towards expansion and greater market presence.

Early Establishment and Manufacturing Strength

Syncom's story began in 1988 when it was founded with a clear vision of becoming a leading manufacturer of pharmaceutical formulations in India. The company’s first manufacturing facility was set up at Palghar, Thane, in 1989, where it started the commercial production of pharmaceutical formulations. The plant was equipped with advanced machinery to maintain the highest quality standards in the industry. The company's portfolio initially focused on producing various dosage forms such as tablets, capsules, and liquid oral preparations.

The promoters of the company—Kedarmal Bankda, Vijay Kumar Bankda, and Ajay Kumar Bankda—have played an integral role in the company’s growth, providing strong leadership and strategic direction. The company's commitment to maintaining high manufacturing standards and delivering quality products allowed it to establish a strong foundation in the Indian pharmaceutical market.

Expansion and Investment in Infrastructure

As Syncom Formulations (India) continued to grow, it expanded its manufacturing capabilities to meet the increasing demand for its products. In 1994, the company embarked on an ambitious expansion program, setting up a new plant in Pithampur, Madhya Pradesh, to manufacture pharmaceutical formulations. The expansion project, which was financed through a public issue in January 1994, was completed in 1995. This new facility enabled the company to significantly increase its production capacity and broaden its product range.

Syncom's strategic focus on enhancing its manufacturing infrastructure did not stop there. In the year 1997-98, the company took a step toward diversifying its operations by introducing a range of ethical formulations. Ethical operations involve the production and marketing of prescription medicines, which are typically sold through healthcare professionals. This marked a turning point for the company, as it ventured into a more specialized and competitive segment of the pharmaceutical industry.

Diversification and Global Reach

By the end of the 1990s, Syncom Formulations (India) had gained a strong foothold in both the domestic and international markets. During the year 1998-99, the company expanded its installed capacity and production base, allowing it to serve the growing demands of various sectors. Additionally, Syncom planned the introduction of products in the generic, over-the-counter (OTC), and ethical divisions, further diversifying its business. This was a strategic decision to target different segments of the pharmaceutical market and strengthen the company's position across various customer bases.

Syncom’s success in domestic markets was accompanied by remarkable growth in its international presence. By 1999-2000, the company had secured export orders worth Rs 700 lakh, contributing significantly to its turnover. The company’s export operations were not limited to a few countries but spanned multiple regions, including Africa and Asia. Syncom Formulations (India) exports its products to countries such as Guinea, Ghana, Kenya, Tanzania, Nigeria, Azerbaijan, Nepal, and Sri Lanka. This expansion into international markets was a critical factor in enhancing the company’s visibility and business growth on the global stage.

Moreover, Syncom’s entry into the public sector market was a major milestone. The company was approved as a supplier to the Central Employees State Insurance (ESI) Hospitals, and it registered with the defense services, which led to a substantial increase in sales volume. As consumer preferences began shifting towards herbal products, Syncom strategically expanded its portfolio to include herbal formulations. Products like Edicare, Attom Megacaps, Ecziguard, and Yas Antacid Salt became part of Syncom's offerings, tapping into the growing demand for natural and plant-based remedies.

Modernization and Capacity Expansion

In the early 2000s, Syncom Formulations (India) continued to focus on modernizing and expanding its manufacturing capabilities. One of the key developments during this period was the modernization of the injectable section of the company’s manufacturing facility. In 2002, Syncom invested in new tunnel systems and other state-of-the-art equipment to improve the efficiency and quality of its injectable products. The tablet department also underwent expansion with the installation of high-speed mega-press machines, enhancing production capacity.

The company did not just focus on modernizing existing units but also expanded its manufacturing capacity. By 2003, Syncom had increased the capacity of its tablet section by 35%, while also doubling the capacity of the capsule section. These expansions allowed the company to meet the growing demand for pharmaceutical formulations both in India and abroad. The expansion was carried out with an investment of Rs 1.34 crore, a significant amount that was used primarily in the 2002-03 fiscal year. The company began utilizing the expanded capacity in May 2003, and this move helped Syncom solidify its position in the industry.

Cratus Life Care Division and Financial Growth

Syncom’s growth trajectory took another leap in 2007 when it launched the Cratus Life Care division to expand its operations further. This division was set up to focus on the marketing and distribution of pharmaceutical products, increasing the company's outreach and strengthening its brand presence. The expansion and modernization project at the Pithampur unit were completed in 2007-08, with a total investment of Rs 15.17 crore.

To fund these expansions, Syncom raised long-term financial resources by issuing 3,10,000 equity shares of Rs. 10 each at a premium of Rs. 36 per share to its promoters in March 2008. These shares were listed on the Bombay Stock Exchange (BSE), which provided the company with greater access to capital and increased its visibility in the financial markets. The proceeds from this issue were used to support the company’s expansion efforts and improve its manufacturing capabilities.

Recent Developments and Shareholder Value

In recent years, Syncom Formulations (India) has continued to evolve and expand its operations. In 2020-21, the company embarked on a significant expansion project, which included increasing its injectable production capacity from 200 lakh to 300 lakh units per annum. In addition, the tablet department was modernized to enhance production efficiency. The overall cost of these expansions was Rs. 40.31 crore, which was funded by the issuance of fresh share capital. This expansion is expected to increase the company's revenue generation capacity and further enhance its competitive edge in the pharmaceutical industry.

The company's share price has been closely followed by investors, with the Syncom Formulations India share price being a key indicator of its financial health and growth potential. The expansion efforts, combined with strategic investments and an increasing focus on ethical and herbal products, suggest that Syncom Formulations (India) is well-positioned for future growth. The company’s commitment to improving manufacturing capabilities, enhancing product offerings, and expanding its market presence is likely to continue driving its growth in the years to come.

Quick overview

Syncom Formulations (India) Limited has come a long way since its establishment in 1988. From its early focus on manufacturing pharmaceutical tablets and capsules to its expansion into injectables, herbal products, and international markets, Syncom has consistently demonstrated its commitment to quality and growth. Through strategic expansions, modernization, and diversification, the company has positioned itself as a significant player in the Indian pharmaceutical industry. With its increasing production capacity and expanding product portfolio, Syncom Formulations (India) is well-poised to continue its growth trajectory, making it an important company to watch in the sector. The Syncom Formulations India share price remains an important indicator of its continued success and future potential.